Elinzanetant: Emerging Therapy for Menopausal Hot Flashes

January 2026

Rx elinzanetant (Lynkuet) is now approved and adds a new nonhormonal option to the menopausal hot flash management toolbox.

Elinzanetant blocks neurokinin 1 (NK1) and neurokinin 3 (NK3) receptors...to reduce substance P and neurokinin B, neurotransmitters that regulate sleep and body temperature.

It’s similar to fezolinetant (Veozah)...an NK3 receptor blocker.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter membership benefits include:

  • 12 issues every year — what you need to know and do, right now
  • Quick, practical reference charts and tools
  • Comprehensive CE library to meet license renewal and state requirements
  • Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
  • Plus much more!

Choose the right tier for your needs today.

Already a subscriber? Log in

Volume pricing available. Get a quote